Sorry Twitter®
this revolution will be written in
165 characters

We are hiring!

We are happy to announce the publication of our collaboration with the Belfer Center at DFCI!

Safer    Faster     Better

165 bases. That is the average length of a piece of tumor DNA floating in a cancer patient’s blood. For Resolution Bioscience’s ctDx™ platform, that small piece of DNA is all that is needed to find the mutation that is driving the disease forward.

cfDNA in Blood

Imagine when a simple blood draw, a "liquid biopsy", will help a physician diagnose and tailor treatment to a tumor’s specific molecular profile.
That future is now.

When we started our company, we asked a simple question: “How can we help patients benefit from the incredible power of next generation sequencing?” That basic question drove us to develop a revolutionary platform that can:

  • see hotspots, indels, amplifications and fusions/translocations
  • in a clinically-relevant 7-day turnaround
  • on a standard desktop sequencer
  • with just 10ml of blood

We even see fusions without prior knowledge of the gene partner or breakpoint — we discover mutations.

The Problem

Imagine being an oncologist treating a non-small cell lung cancer (NSCLC) patient. You know that a targeted therapy may help your patient, but which test should you order? EGFR? ALK? What about BRAF? MET amplification? What if the patient is frail or the tumor is hard to biopsy? What if you can’t wait a month for a tissue-based molecular report?


Gotta see them all
of lung biopsies have complications, increasing costs by 400%1
which to test first?
single analyte tests are not a clinical solution
Biopsies may provide
views of tumor heterogeneity
average cost of a lung biopsy
time it can take to obtain a biopsy and molecular profile
1,22014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Our Solution

We start with 10ml of peripheral blood. We extract the circulating, cell-free DNA (cfDNA), of which a fraction of the cfDNA is from the cancer tumor (ctDNA). Through proprietary biochemistry, we molecularly tag millions of cfDNA fragments, and discover driver mutations by sequencing them on a desktop sequencer. Our cloud-based bioinformatics analyzes the data and produces a comprehensive variant report. Hotspots, indels, amplifications and fusions — we see them all in a single assay from a single sample. Our process is so efficient that we routinely multiplex samples in a single sequencing run.

After sequencing, our novel bioinformatics analyzes millions of reads. In a single assay we capture all types of mutations. The result:

a comprehensive, actionable molecular profile report within 7 days.

In May 2015, we launched our ctDX ALK assay from our CLIA lab. We continue to validate our gene panel for NSCLC, ctDx Lung. Being a true platform, we can easily and efficiently add new genes as science discovers new driver mutations and new therapies are developed.

Our plans include developing a kit that will enable any lab with a desktop sequencer to run the Resolution ctDx platform. Sequencing data can be streamed to our cloud-based bioinformatics.

We will enable researchers around the globe to develop novel assays. We will create pan-therapy companion diagnostics (CDx) assays that can be run anywhere in the world.

We want to make a difference.



Within these vials of human plasma reside the keys to understanding what is driving these patients disease. In a safe and routine blood draw, we can unlock information to help a physician direct therapy decisions.

Not every tumor can be biopsied. Not every biopsy results in enough tumor cells to give a definitive molecular profile. Biopsies can result in serious complications. Serial biopsies are not practical. As the tumor finds new ways to escape therapy, plasma offers the ability to continually monitor tumor evolution — providing critical, real-time feedback to direct therapeutic decisions.

Read more